))
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing the Effective Delivery of Cannabinoids
Manage episode 395931796 series 3529176
Content provided by podcast@investorbrandnetwork.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by podcast@investorbrandnetwork.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment. GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), which has won widespread praise for its innovative medical work, has seen good trial results for a new treatment for seizures. Tilray Inc. (NASDAQ: TLRY) is supporting studies into the uses of cannabinoids to treat behavioral problems and HIV. MariMed Inc. (OTCQB: MRMD) has set up a subsidiary focused on CBD, currently the highest-profile cannabinoid product. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has established a new research lab to develop devices for CBD consumption.
58 episodes
Share
